CATIE looks at some of the approaches in Canada and globally that help improve sex workers' access to HIV prevention and care services in a criminalized environment.
On behalf of IFARA, Fred Schaich spoke with Zeda Rosenberg at this year's International AIDS Conference about final trial results showing the safety and efficacy -- when used -- of a vaginal ring in preventing HIV.
A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent.
Three studies conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in rural and urban sub-districts of the KwaZulu-Natal province provide new insights into the engine that drives HIV transmission in the country. They a...
Long-acting anti-HIV drugs have been in development longer than their oral, immediate-release counterparts. Some of the reasons for the longer development of these drugs arise because these formulations are new and have not been previously been teste...
Data from two large-scale dapivirine vaginal ring trials were reported at CROI 2016 and it works. Modestly. What's next?
Follow-up studies, including an open-label extension, on the dapivirine vaginal ring look to build on the initial modest results of 27% overall reduction in HIV transmission.
NHS England Pulls Proposed Timeline for PrEP: Perpetuates HIV Health Crisis in Gay Men and Trans People
Simon Collins of HIV i-Base reacts scathingly to England's apparent decision to "block access to the most effective new option for protecting people at highest risk from catching HIV."
There is hope for an HIV-prevention product that people could essentially use in place of a lube. But can gels provide enough coverage across rectal tissue if people don't use an applicator?
Although the CCR5 inhibitor maraviroc is largely underused as an antiretroviral drug, several studies looking at whether it has a role as PrEP seem to support use in combinations.